OBJECTIVE: Rapid thrombus recanalization reduces the incidence of post-thrombotic complications. This study aimed to discover whether adenovirus-mediated transfection of the vascular endothelial growth factor gene (ad.VEGF) enhanced thrombus recanalization and resolution. METHODS AND RESULTS: In rats, thrombi were directly injected with either ad.VEGF (n=40) or ad.GFP (n=37). Thrombi in SCID mice (n=12) were injected with human macrophages transfected with ad.VEGF or ad.GFP. Thrombi were analyzed at 1 to 14 days. GFP was found mainly in the vein wall and adventitia by 3 days, but was predominantly found in cells within the body of thrombus by day 7. VEGF levels peaked at 4 days (376+/-299 pg/mg protein). Ad.VEGF treatment reduced thrombus size by >50% (47.7+/-5.1 mm(2) to 22.0+/-4.0 mm(2), P=0.0003) and increased recanalization by >3-fold (3.9+/-0.69% to 13.6+/-4.1%, P=0.024) compared with controls. Ad.VEGF treatment increased macrophage recruitment into the thrombus by more than 50% (P=0.002). Ad.VEGF-transfected macrophages reduced thrombus size by 30% compared with controls (12.3+/-0.89 mm(2) to 8.7+/-1.4 mm(2), P=0.04) and enhanced vein lumen recanalization (3.39+/-0.34% to 5.07+/-0.57%, P=0.02). CONCLUSIONS: Treatment with ad.VEGF enhanced thrombus recanalization and resolution, probably as a consequence of an increase in macrophage recruitment.
OBJECTIVE: Rapid thrombus recanalization reduces the incidence of post-thrombotic complications. This study aimed to discover whether adenovirus-mediated transfection of the vascular endothelial growth factor gene (ad.VEGF) enhanced thrombus recanalization and resolution. METHODS AND RESULTS: In rats, thrombi were directly injected with either ad.VEGF (n=40) or ad.GFP (n=37). Thrombi in SCIDmice (n=12) were injected with human macrophages transfected with ad.VEGF or ad.GFP. Thrombi were analyzed at 1 to 14 days. GFP was found mainly in the vein wall and adventitia by 3 days, but was predominantly found in cells within the body of thrombus by day 7. VEGF levels peaked at 4 days (376+/-299 pg/mg protein). Ad.VEGF treatment reduced thrombus size by >50% (47.7+/-5.1 mm(2) to 22.0+/-4.0 mm(2), P=0.0003) and increased recanalization by >3-fold (3.9+/-0.69% to 13.6+/-4.1%, P=0.024) compared with controls. Ad.VEGF treatment increased macrophage recruitment into the thrombus by more than 50% (P=0.002). Ad.VEGF-transfected macrophages reduced thrombus size by 30% compared with controls (12.3+/-0.89 mm(2) to 8.7+/-1.4 mm(2), P=0.04) and enhanced vein lumen recanalization (3.39+/-0.34% to 5.07+/-0.57%, P=0.02). CONCLUSIONS: Treatment with ad.VEGF enhanced thrombus recanalization and resolution, probably as a consequence of an increase in macrophage recruitment.
Authors: Crystal M Ripplinger; Chase W Kessinger; Chunqiang Li; Jin Won Kim; Jason R McCarthy; Ralph Weissleder; Peter K Henke; Charles P Lin; Farouc A Jaffer Journal: Arterioscler Thromb Vasc Biol Date: 2012-09-20 Impact factor: 8.311
Authors: Christine Chabasse; Suzanne A Siefert; Mohammed Chaudry; Mark H Hoofnagle; Brajesh K Lal; Rajabrata Sarkar Journal: J Vasc Surg Venous Lymphat Disord Date: 2014-05-10
Authors: Steven P Grover; Colin E Evans; Ashish S Patel; Bijan Modarai; Prakash Saha; Alberto Smith Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-17 Impact factor: 8.311
Authors: Julia Humphries; James A Gossage; Bijan Modarai; Kevin G Burnand; Thomas H Sisson; Colin Murdoch; Alberto Smith Journal: J Vasc Surg Date: 2009-08-22 Impact factor: 4.268
Authors: Prakash Saha; Julia Humphries; Bijan Modarai; Katherine Mattock; Matthew Waltham; Colin E Evans; Anwar Ahmad; Ashish S Patel; Sobath Premaratne; Oliver T A Lyons; Alberto Smith Journal: Arterioscler Thromb Vasc Biol Date: 2011-03 Impact factor: 8.311
Authors: Sherin Alias; Bassam Redwan; Adelheid Panzenboeck; Max P Winter; Uwe Schubert; Robert Voswinckel; Maria K Frey; Johannes Jakowitsch; Arman Alimohammadi; Lukas Hobohm; Andreas Mangold; Helga Bergmeister; Maria Sibilia; Erwin F Wagner; Eckhard Mayer; Walter Klepetko; Thomas J Hoelzenbein; Klaus T Preissner; Irene M Lang Journal: Arterioscler Thromb Vasc Biol Date: 2014-02-13 Impact factor: 8.311